transforming-growth-factor-alpha and Crohn-Disease

transforming-growth-factor-alpha has been researched along with Crohn-Disease* in 4 studies

Other Studies

4 other study(ies) available for transforming-growth-factor-alpha and Crohn-Disease

ArticleYear
A possible link between TIMP-1 induction and response to infliximab.
    Gut, 2009, Volume: 58, Issue:6

    Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal; Apoptosis; Crohn Disease; Humans; Infliximab; Tissue Inhibitor of Metalloproteinase-1; Transforming Growth Factor alpha

2009
Transforming growth factor-alpha and epidermal growth factor receptor in colonic mucosa in active and inactive inflammatory bowel disease.
    Growth factors (Chur, Switzerland), 2000, Volume: 18, Issue:2

    Transforming growth factor-alpha (TGF-alpha) is overexpressed in colonic carcinomas and promotes mucosal wound healing. It may be implicated in chronic inflammatory bowel disease (IBD). We analyzed the expression of TGF-alpha and its receptor, epidermal growth factor receptor (EGF-r), in the colonic mucosa of patients with Crohn's disease (CD) or ulcerative colitis (UC), in active or inactive stages, as compared with controls. Proteins and mRNA were detected in biopsies from the right and left colon and in surgical colonic specimens. Immunoblot analysis revealed TGF-alpha protein as a 29 kDa band. This band was normally expressed in uninvolved colonic mucosa of patients with CD or UC whether in active or inactive stages, but decreased or absent in involved mucosa of active IBD, even when TGF-alpha mRNA and EGF-r protein were detected. In the unaffected mucosa of CD, the intensity of TGF-alpha immunoreactivity was similar to that of controls in the right colon but stronger (P = 0.05) in the left colon. There was no TGF-alpha overexpression in dysplastic regions. In conclusion, in active IBD disease, the decreased TGF-alpha protein amount seems not only related to epithelial cell loss but reflects a down-regulation at least at the protein level. We speculate that TGF-alpha does not play a role within the active stage but may be implicated later in the repair process.

    Topics: Adult; Aged; Aged, 80 and over; Biopsy; Blotting, Western; Colitis, Ulcerative; Colon; Colonoscopy; Crohn Disease; ErbB Receptors; Female; Humans; Immunohistochemistry; Inflammatory Bowel Diseases; Intestinal Mucosa; Male; Middle Aged; Tissue Distribution; Transforming Growth Factor alpha

2000
Modification of in vivo and in vitro TNF-alpha, IL-1, and IL-6 secretion by circulating monocytes during hyperbaric oxygen treatment in patients with perianal Crohn's disease.
    Journal of clinical immunology, 1997, Volume: 17, Issue:2

    Treatment of perianal inflammatory lesions in Crohn's disease (CD) is unsatisfactory and novel treatment modalities are pursued. We have recently reported a good clinical effect of hyperbaric oxygen (HBO) treatment in perianal CD. In the present study, seven patients with perianal CD were subjected to daily sessions of HBO in a multiplace hyperbaric chamber. Each patient received a total of 20 sessions during a time period of 1 month, and IL-1, IL-6, and TNF-alpha measurements were done several times during the initial sessions and after completing therapy. Pretreatment cytokine levels were elevated in patients compared to age-matched 10 normal controls. During the first 7 days of treatment, IL-1, IL-6, and TNF-alpha levels in supernatants of LPS-stimulated monocytes derived from patients' peripheral blood were decreased compared to pretreatment levels. Parallel measurements of serum IL-1 levels revealed an initial elevation and thereafter decreased levels, which remained low throughout the first week of HBO treatment. After completion of therapy, cytokine levels increased to pretreatment values. We conclude that alterations in secretion of IL-1, IL-6, and TNF-alpha may be related to the good clinical effect of HBO treatment in CD patients with perianal disease.

    Topics: Adult; Biomarkers; Crohn Disease; Female; Humans; Hyperbaric Oxygenation; Interleukin-1; Interleukin-6; Male; Middle Aged; Monocytes; Transforming Growth Factor alpha

1997
Expression of transforming growth factors alpha and beta in colonic mucosa in inflammatory bowel disease.
    Gastroenterology, 1996, Volume: 110, Issue:4

    Transforming growth factors (TGFs) alpha and beta are key regulatory peptides that modulate mucosal cell populations critical to inflammatory bowel disease. The aim of this study was to assess TGF-alpha and TGF-beta expression in human colonic mucosa.. TGF-alpha and TGF-beta expression was assessed in colonic mucosa from patients with ulcerative colitis, patients with Crohn's disease, and controls by Northern blot analysis, in situ hybridization, and bioassay.. TGF-alpha messenger RNA expression localized to the villous tips of the small intestine and the surface epithelium of the colon. TGF-alpha expression was enhanced 2.3-fold in inactive ulcerative colitis mucosa relative to active ulcerative colitis, Crohn's disease, or normal controls. Enhanced expression correlated with duration of disease. TGF-beta expression was increased in affected mucosa from both patients with ulcerative colitis and Crohn's disease with active disease. TGF-beta1 messenger RNA expression in ulcerative colitis and Crohn's disease localized mostly to cells of the lamina propria with the highest concentration in inflammatory cells closest to the luminal surface.. TGF-alpha may contribute to epithelial hyperproliferation and the increased risk of malignancy in long-standing ulcerative colitis. TGF-beta may be a key cytokine during periods of active inflammation, modulating epithelial cell restitution and functional features of cells within the lamina propria.

    Topics: Biological Assay; Blotting, Northern; Colitis, Ulcerative; Colon; Crohn Disease; Epithelium; Humans; In Situ Hybridization; Inflammatory Bowel Diseases; Intestinal Mucosa; RNA, Messenger; Transforming Growth Factor alpha; Transforming Growth Factor beta

1996
chemdatabank.com